X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (156756) 156756
Magazine Article (210) 210
Newsletter (139) 139
Newspaper Article (50) 50
Publication (45) 45
Book / eBook (40) 40
Transcript (25) 25
Dissertation (22) 22
Conference Proceeding (12) 12
Book Chapter (10) 10
Book Review (7) 7
Web Resource (7) 7
Reference (3) 3
Report (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (151219) 151219
antineoplastic combined chemotherapy protocols - therapeutic use (106975) 106975
female (96401) 96401
male (79536) 79536
middle aged (73076) 73076
oncology (72355) 72355
adult (60571) 60571
aged (59728) 59728
chemotherapy (45088) 45088
treatment outcome (37201) 37201
cancer (35450) 35450
antineoplastic combined chemotherapy protocols - adverse effects (31180) 31180
combined modality therapy (28586) 28586
prognosis (23820) 23820
antineoplastic combined chemotherapy protocols - administration & dosage (21979) 21979
neoplasm staging (20731) 20731
cisplatin - administration & dosage (20233) 20233
hematology (17932) 17932
aged, 80 and over (17330) 17330
adolescent (16746) 16746
survival rate (16736) 16736
retrospective studies (16214) 16214
disease-free survival (16034) 16034
fluorouracil - administration & dosage (15863) 15863
therapy (15555) 15555
animals (15220) 15220
care and treatment (15162) 15162
breast neoplasms - drug therapy (14801) 14801
doxorubicin - administration & dosage (14648) 14648
antineoplastic agents - therapeutic use (14613) 14613
cyclophosphamide - administration & dosage (14328) 14328
follow-up studies (13992) 13992
survival analysis (13648) 13648
survival (13558) 13558
lung neoplasms - drug therapy (13204) 13204
drug administration schedule (13009) 13009
chemotherapy, adjuvant (12446) 12446
cisplatin (12425) 12425
medicine & public health (11744) 11744
child (11603) 11603
remission induction (11000) 11000
surgery (10806) 10806
radiotherapy (10210) 10210
vincristine - administration & dosage (10198) 10198
research (9876) 9876
cell line, tumor (9767) 9767
carcinoma (9732) 9732
tumors (9437) 9437
mice (9346) 9346
breast cancer (9155) 9155
analysis (8987) 8987
trial (8891) 8891
pharmacology & pharmacy (8827) 8827
time factors (8681) 8681
dose-response relationship, drug (8521) 8521
breast neoplasms - pathology (8343) 8343
deoxycytidine - analogs & derivatives (8240) 8240
antineoplastic agents - administration & dosage (8197) 8197
child, preschool (8190) 8190
etoposide - administration & dosage (8165) 8165
prospective studies (8028) 8028
metastasis (8017) 8017
hematology, oncology and palliative medicine (7981) 7981
antineoplastic agents (7713) 7713
paclitaxel - administration & dosage (7692) 7692
antineoplastic combined chemotherapy protocols - pharmacology (7680) 7680
apoptosis (7660) 7660
carcinoma, non-small-cell lung - drug therapy (7578) 7578
health aspects (7549) 7549
young adult (7529) 7529
neoplasm metastasis (7287) 7287
adenocarcinoma - drug therapy (7234) 7234
risk factors (7091) 7091
clinical trials as topic (7066) 7066
antimitotic agents (6919) 6919
antineoplastic agents - pharmacology (6787) 6787
drug therapy (6746) 6746
expression (6739) 6739
carboplatin - administration & dosage (6662) 6662
antineoplastic combined chemotherapy protocols (6655) 6655
deoxycytidine - administration & dosage (6617) 6617
neoplasms - drug therapy (6507) 6507
paclitaxel (6492) 6492
methotrexate - administration & dosage (6465) 6465
combination (6400) 6400
recurrence (6260) 6260
lung neoplasms - pathology (6051) 6051
doxorubicin (6041) 6041
cyclophosphamide (5976) 5976
neoadjuvant therapy (5926) 5926
colorectal neoplasms - drug therapy (5920) 5920
fluorouracil (5894) 5894
clinical trials (5875) 5875
prednisone - administration & dosage (5855) 5855
apoptosis - drug effects (5805) 5805
ovarian neoplasms - drug therapy (5804) 5804
cancer therapies (5717) 5717
disease progression (5683) 5683
antineoplastic agents - adverse effects (5624) 5624
phase-ii (5616) 5616
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (15) 15
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (141528) 141528
Japanese (9405) 9405
German (2583) 2583
French (2552) 2552
Chinese (2396) 2396
Russian (1354) 1354
Spanish (934) 934
Italian (650) 650
Polish (624) 624
Hungarian (290) 290
Dutch (168) 168
Portuguese (145) 145
Czech (125) 125
Danish (73) 73
Romanian (60) 60
Ukrainian (59) 59
Hebrew (53) 53
Norwegian (46) 46
Korean (44) 44
Bulgarian (43) 43
Serbian (43) 43
Croatian (33) 33
Finnish (31) 31
Swedish (18) 18
Turkish (14) 14
Slovak (13) 13
Bosnian (10) 10
Lithuanian (8) 8
Afrikaans (2) 2
Arabic (1) 1
Manx (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
... than standard chemotherapy in patients with ALK -positive lung cancer. Rearrangements of the anaplastic lymphoma kinase ( ALK... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
...) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 3, pp. 230 - 240
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 8, pp. CD004064 - CD004064
... to HER‐2 positive disease treated with trastuzumab, in combination with chemotherapy, in first... 
Camptothecin | Stomach | Anthracyclines | Gastroenterology & hepatology | Cancer: other gastrointestinal | Palliation | Docetaxel | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Randomized Controlled Trials as Topic | Irinotecan | Chemotherapy | Treatment | Taxoids | Stomach Neoplasms | Medicine General & Introductory Medical Sciences | Fluorouracil | Cancer | 1ST-LINE TREATMENT | OLDER-ADULT PATIENTS | COLONY-STIMULATING FACTOR | Humans | Anthracyclines [administration & dosage] | Cisplatin [administration & dosage] | HIGH-DOSE 5-FLUOROURACIL | Fluorouracil [administration & dosage] | MEDICINE, GENERAL & INTERNAL | analogs & derivatives | RANDOMIZED PHASE-II | ADVANCED GASTROINTESTINAL CANCER | mortality | Taxoids [administration & dosage] | Antineoplastic Combined Chemotherapy Protocols [therapeutic use] | QUALITY-OF-LIFE | GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA | Camptothecin [administration & dosage | Stomach Neoplasms [drug therapy | S-1 PLUS CISPLATIN | COOPERATIVE-ONCOLOGY-GROUP | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Taxoids - administration & dosage | Anthracyclines - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Camptothecin - administration & dosage | Stomach Neoplasms - mortality | Camptothecin - analogs & derivatives | Index Medicus
Journal Article